个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Zhang Cheng[1,2,3] * ; Wang Xiaoqi[1,2,3] * ; Yi Hai[4] ; Wang Yi[5] ; Yan Zhiling[6] ; Zhou Jian[7] ; Yang Ting[8] ; Liang Aibin[9] ; Wang Zhen[10] ; Ma Yingying[1,2,3] ; Wen Qin[1,2,3] ; Gao Lei[1,2,3] ; Gao Li[1,2,3] ; Kong Peiyan[1,2,3] ; Tan Xu[1,2,3] ; Jiang Erlie[11] ; Zhang Xi[1,2,3] ;
机构： [1]Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing, 400037, China. [2]Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing, 400037, China. [3]State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing, 400037, China. [4]Department of Hematology, Sichuan Clinical Research Center for Hematological Disease. Branch of National Clinical Research Center for Hematological Disease, The General Hospital of Western Theater Command, Chengdu, 610000, China. [5]Department of Hematology, Shaanxi Provincial Peoples Hospital, Xi'an, 710068, China. [6]Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China. [7]Department of Haematology, the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Henan, 450008, China. [8]Department of Hematology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, 350005, China. [9]Department of Hematology, Tongji Hospital of Tongji University, Shanghai, 200092, China. [10]Department of Hematology, Henan Provincial People's Hospital, People's Hospital of Henan University, Henan, 450003, China. [11]Center of Hematopoietic Stem Cell Transplantation, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300200, China.
出处：
DOI： 10.1186/s13045-024-01626-6

关键词： Donor-derived CD19 CAR-T Allo-HSCT Relapsed Long-term survival

摘要：
Chimeric Antigen Receptor T (CAR-T) cell therapy has significantly advanced in treating B-cell acute lymphoblastic leukemia (B-ALL) and has shown efficacy in managing relapsed B-ALL after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Donor-derived CAR-T cell offer both high efficacy and rapid response. Although promising results exist, current research lacks definitive evidence of long-term survival benefits for patients treated with donor-derived CAR-T therapy. We report the long-term survival of 32 patients with post-transplant relapsed B-ALL treated with donor-derived CD19 CAR-T cell, achieving either complete Remission (CR) or CR with incomplete peripheral blood recovery (CRi). The median follow-up was 42 months, with 2-year overall survival (OS) and event-free survival (EFS) rates of 56.25% and 50.0%, respectively. The 5-year OS and EFS rates were 53.13% and 46.88%, with no new long-term adverse events observed. These findings demonstrate good long-term safety, supporting donor-derived CAR-T cell as a recommended treatment option for relapsed B-ALL patients post-transplantation. Trial registration: https://www.chictr.org.cn/showproj.html?proj=14315 . Registration number: ChiCTR-OOC-16008447.© 2024. The Author(s).

基金：
National Natural Science Foundation of China (Grant No. 82341201, 82370181), the National Key R&D Program of China (Grant No. 2022YFA1103300, 2022YFA1103304), and the Special Project for Talent Construction in Xinqiao Hospital (Grant No. 2022XKRC001, 2022YQB004).
语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2024]版：
无
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 血液学 1 区 肿瘤学
JCR分区：
出版当年[2024]版：
无
最新[2023]版：
Q1 HEMATOLOGY Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2023版]

第一作者：
第一作者机构： [1]Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing, 400037, China. [2]Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing, 400037, China. [3]State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing, 400037, China.
共同第一作者：
通讯作者：
通讯机构： [1]Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing, 400037, China. [2]Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing, 400037, China. [3]State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing, 400037, China.
推荐引用方式(GB/T 7714)：
Zhang Cheng,Wang Xiaoqi,Yi Hai,et al.Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation[J].Journal Of Hematology & Oncology.2024,17(1):103.doi:10.1186/s13045-024-01626-6.
APA：
Zhang Cheng,Wang Xiaoqi,Yi Hai,Wang Yi,Yan Zhiling...&Zhang Xi.(2024).Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation.Journal Of Hematology & Oncology,17,(1)
MLA：
Zhang Cheng,et al."Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation".Journal Of Hematology & Oncology 17..1(2024):103

相关文献

[1]The modified melphalan and busulfan-based regimen combined with maintenance therapy improved the survival of patients with refractory/relapsed AML after allogeneic transplantation: middle-term outcome of a multicenter trial [2]Long-Term Survival after Surgical Treatment for Thymic Carcinoma [3]Effects of Intraoperative Targeted Temperature Management on Incidence of Postoperative Delirium and Long-term Survival [4]Lymph node dissection in small-sized pulmonary metastasectomy: Impact on the long-term survival [5]ASO Author Reflections: Prediction of Long-Term Cancer-Specific Survival of Lung Carcinoid Patients [6]A multifactorial risk scoring system for the prediction of early relapse in CMML patients with allo-HSCT: a nationwide representative multicenter study [7]Long-Term Survival of Patients With Chemotherapy-Naive Metastatic Nasopharyngeal Carcinoma Receiving Cetuximab Plus Docetaxel and Cisplatin Regimen [8]Long-term survival among patients with gastrointestinal stromal tumors diagnosed after another malignancy: a SEER population-based study. [9]Comparison of Long-term Survival of Patients With Locally Advanced Lung Cancer After Video-Assisted Thoracoscopic Surgery Versus Thoracotomy [10]Preoperative short-course radiotherapy and long-course radiochemotherapy for locally advanced rectal cancer: Meta-analysis with trial sequential analysis of long-term survival data.

资源点击量：52808 今日访问量：0 总访问量：4561 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号